1030 related articles for article (PubMed ID: 30420753)
1. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.
Wang Z; Aguilar EG; Luna JI; Dunai C; Khuat LT; Le CT; Mirsoian A; Minnar CM; Stoffel KM; Sturgill IR; Grossenbacher SK; Withers SS; Rebhun RB; Hartigan-O'Connor DJ; Méndez-Lagares G; Tarantal AF; Isseroff RR; Griffith TS; Schalper KA; Merleev A; Saha A; Maverakis E; Kelly K; Aljumaily R; Ibrahimi S; Mukherjee S; Machiorlatti M; Vesely SK; Longo DL; Blazar BR; Canter RJ; Murphy WJ; Monjazeb AM
Nat Med; 2019 Jan; 25(1):141-151. PubMed ID: 30420753
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer.
Pingili AK; Chaib M; Sipe LM; Miller EJ; Teng B; Sharma R; Yarbro JR; Asemota S; Al Abdallah Q; Mims TS; Marion TN; Daria D; Sekhri R; Hamilton AM; Troester MA; Jo H; Choi HY; Hayes DN; Cook KL; Narayanan R; Pierre JF; Makowski L
Cell Rep; 2021 Jun; 35(12):109285. PubMed ID: 34161764
[TBL] [Abstract][Full Text] [Related]
3. Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery.
Sipe LM; Chaib M; Korba EB; Jo H; Lovely MC; Counts BR; Tanveer U; Holt JR; Clements JC; John NA; Daria D; Marion TN; Bohm MS; Sekhri R; Pingili AK; Teng B; Carson JA; Hayes DN; Davis MJ; Cook KL; Pierre JF; Makowski L
Elife; 2022 Jul; 11():. PubMed ID: 35775614
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment.
Le CT; Khuat LT; Caryotakis SE; Wang M; Dunai C; Nguyen AV; Vick LV; Stoffel KM; Blazar BR; Monjazeb AM; Murphy WJ; Soulika AM
Front Immunol; 2020; 11():590568. PubMed ID: 33193426
[TBL] [Abstract][Full Text] [Related]
5. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
[TBL] [Abstract][Full Text] [Related]
6. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
9. Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
Foy SP; Sennino B; dela Cruz T; Cote JJ; Gordon EJ; Kemp F; Xavier V; Franzusoff A; Rountree RB; Mandl SJ
PLoS One; 2016; 11(2):e0150084. PubMed ID: 26910562
[TBL] [Abstract][Full Text] [Related]
10. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS; Arlauckas SP; Kohler RH; Trefny MP; Garren S; Piot C; Engblom C; Pfirschke C; Siwicki M; Gungabeesoon J; Freeman GJ; Warren SE; Ong S; Browning E; Twitty CG; Pierce RH; Le MH; Algazi AP; Daud AI; Pai SI; Zippelius A; Weissleder R; Pittet MJ
Immunity; 2018 Dec; 49(6):1148-1161.e7. PubMed ID: 30552023
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
12. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
13. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
Front Immunol; 2019; 10():491. PubMed ID: 30936880
[TBL] [Abstract][Full Text] [Related]
14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
15. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
[TBL] [Abstract][Full Text] [Related]
16. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
17. Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma.
Galvin KC; Conroy MJ; Doyle SL; Dunne MR; Fahey R; Foley E; O'Sullivan KE; Doherty DG; Geoghegan JG; Ravi N; O'Farrelly C; Reynolds JV; Lysaght J
Cancer Lett; 2018 Apr; 418():230-238. PubMed ID: 29339209
[TBL] [Abstract][Full Text] [Related]
18. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
20. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]